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to the lack of appropriate loss-of-function mouse models and redundant effects with other Bcl-2
pro-survival proteins upon overexpression. Expression analysis of A1 suggests predominant
roles in leukocyte development, their survival upon viral or bacterial infection, as well as during
allergic reactions. In addition, A1 has been implicated in autoimmunity and the pathology and therapy
resistance of hematological as well as solid tumors that may aberrantly express this protein. In this re-
view,weaim to summarize current knowledge onA1biology, focusing on its role in the immune system
and compare it to that of other pro-survival Bcl-2 proteins.
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Two convergent pathways are involved in the induction of apo-
ptosis: the “extrinsic” and the “intrinsic” pathway. The extrinsic
pathway, also called the “death receptor” (DR) pathway, is initiated
by the ligation of Tumor Necrosis Factor Receptor (TNF-R) family
members that contain a cytoplasmic death domain (DD)with a spe-
cific “death ligand” of the TNF-family. This triggers the formation of
the death-inducing signaling complex (DISC) that leads to the
activation of apoptotic proteases of the caspase family, i.e. the
initiator pro-caspase-8 and/or, in humans, also pro-caspase-10
[1–3].
The intrinsic pathway, also known as “mitochondrial” path-
way, is responsible for the induction of apoptosis in response to,
e.g. DNA damaging agents, altered redox status or endoplasmatic
reticulum (ER) stress. Importantly, also cytokine- or growth
factor-withdrawal as well as high-affinity ligation of antigen re-
ceptors during negative selection processes in the developing im-
mune system triggers mitochondrial apoptosis [4]. All these
stimuli cause increased mitochondrial permeability, often referred
to as mitochondrial outer membrane permeabilization (MOMP),
which induces the release of cytochrome C from the inter-
membrane space, which binds the WD-40 repeats of the cytoplas-
mic adaptor protein Apaf-1. Upon binding to cytochrome C and
using dATP/ATP as a cofactor, Apaf-1 undergoes a conformational
change that recruits pro-caspase-9 molecules via caspase recruit-
ment domain (CARD)-dependent interaction. This in turn medi-
ates the full activation of initiator pro-caspase-9 molecules by
autoprocessing in the apoptosome complex [3]. In addition the
permeabilization of the mitochondrial outer membrane leads to
the release of the apoptogenic proteins such as SMAC/DIABLO
and HtrA2/Omi that inhibit caspase-inhibitors of the “inhibitor of
apoptosis” (IAP) family, mainly XIAP, that blocks caspase-9 and
caspase-3 activity, amplifying apoptotic signals [5]. MOMP ulti-
mately also associates with the release of additional cell death
promoting molecules such as endo-G or AIF that both possess nu-
clease activities but may be more critical for non-apoptotic cell
death paradigms [6,7].
In certain cell types, including hepatocytes and pancreatic beta
cells, as well as in certain tumors, the intrinsic pathway can con-
nect and enhance the pro-apoptotic potential of the extrinsic
pathway via caspase-8-mediated proteolysis of the Bcl-2 family
protein Bid, that can trigger MOMP in its processed truncated
form, tBid [2]. tBid has also been implicated in a special form of
cell death that does not easily fall in one of the two aforemen-
tioned categories of apoptosis. In the immune system, the per-
forin/granzyme pathway can be considered as an additional
special paradigm of apoptosis. It is induced in infected target
cells by cytotoxic T cells through the activation of apoptotic prote-
ases of the caspase-family at a level where usually both, the ex-
trinsic and intrinsic apoptosis pathways, converge, i.e. the direct
activation of caspase-3/7 zymogens. NK cells can make use of the
same cell death pathway attacking transformed cells lacking MHC-
class-I expression on their cell surface. Granzyme-B-mediated pro-
cessing of Bid may also amplify the death signal, similar to that
seen upon death receptor ligation in hepatocytes. However, here
species-specific differences seem to apply as only the human en-
zyme processes Bid effectively, while mouse granzyme B cleaves
Bid only with very low efficacy [8].The Bcl-2 family
Key-players of the intrinsic apoptotic pathway are the Bcl-2 family
proteins. Bcl-2 was first identified as a protein upregulated in
human follicular B cell lymphoma, following the t(14;18) chromo-
somal translocation of the BCL-2 gene juxtaposing it to the Ig
heavy-chain locus [9,10]. The Bcl-2 family members show se-
quence and structural similarity in their “Bcl-2 homology regions”
(referred to as BH-domains) and can be divided into two sub-
groups according to their function: anti- and pro-apoptotic pro-
teins. The pro-apoptotic members can be further subdivided into
the Bax/Bak-like proteins, i.e. Bax, Bak and Bok, which share
three BH-regions with their pro-survival relatives (therefore
sometimes also referred to as BH-123 proteins) and the BH3-
only proteins (Bad, Bid, Bik, Bim, Bmf, Hrk, Noxa and Puma) that
only contain the BH3-domain but are otherwise only poorly con-
served amongst each other and all other Bcl-2 family members
[2,3]. Bax and Bak proteins regulate the permeabilization of the
mitochondrial outer membrane and their promiscuity in cell
death signaling has been confirmed by gene targeting studies in
mice showing redundant function in cell death initiation [11]. In
contrast, the role of Bok, if any in this process, is still unknown.
Once activated, Bax and Bak proteins can form homo-oligomers
in the outer mitochondrial membrane that leads to the formation
of a pore-like structure which then triggers the subsequent dis-
ruption of the membrane integrity and the release of cytochrome
C, followed by caspase activation. The precise structure of the Bax/
Bak pore, however, remains to be determined [2,3]. In healthy
cells the anti-apoptotic members of the Bcl-2 family (Bcl-2, Bcl-
xL, Bcl-w, Mcl-1, A1/Bfl-1) sequester Bak and neutralize or
restrain activated Bax in the cytosol, thereby preventing MOMP.
However, it remains to be determined if all these proteins prevent
MOMP by exactly the same molecular mechanism(s). Upon differ-
ent stress stimuli, sentinel BH3-only proteins become activated or
transcribed/translated and initiate the apoptotic cascade leading
to Bax/Bak activation [12]. The molecular mechanism underlying
the BH3-only protein-mediated activation of Bax/Bak is still debat-
ed. In the so-called “affinity model”, BH3-only proteins are able to
bind to a hydrophobic groove on the surface of the anti-apoptotic
Bcl-2 family members, preventing them from counteracting the
apoptotic activity of Bax/Bak. This interaction is dependent on
the characteristics of the BH3-domain. Hence each BH3-only pro-
tein has a certain preference for one or more proteins of the
anti-apoptotic family. In an alternative model, referred to as “di-
rect activation” model, all the BH3 only proteins compete for the
binding to the anti-apoptotic members of the family, but only
Bid, Bim and probably also Puma can induce direct conformational
changes in Bax or Bak that promote their targeting (in the case of
Bax) to and oligomerization in the outer mitochondrial mem-
brane. Recently, evidence has been provided that both mecha-
nisms are able to cooperate in cell death induction [13,14].
The apoptotic threshold is tightly regulated by the balance be-
tween pro- and anti-apoptotic Bcl-2 family proteins present in a
given cell type [12]. In healthy cells, pro-survival pathways includ-
ing those triggered upon growth factor or cytokine-mediated acti-
vation of protein kinase networks, such as ERK or AKT, can
stimulate the transcriptional induction of anti-apoptotic Bcl-2
family members. Expression levels of Bax and Bak are usually sta-
ble in most cells and barely subjected to transcriptional regulation
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On the other hand, BH3-only proteins are held in check by very di-
versemechanisms. For example, Noxa and Puma are frequently con-
trolled at the transcriptional level. Bim, Bmf or Bad abundance and/
or activity are most frequently regulated post-transcriptionally, e.g.
by IRES-dependent translation [15], subcellular sequestration or
phosphorylation events, e.g. by above-mentioned kinases or their
effectors, controlling their interaction capacity with Bcl-2 pro-
survival homologues [12,16]. As indicated above, proteolysis of Bid,
by caspases or granzyme-B, regulates its pro-apoptotic activity [8].
Each BH3-only protein is considered to transmit a distinct set
of death signals, albeit redundancy and cell-type specific re-
sponses are frequently observed. For example loss of Bim impairs
the response of lymphocytes to cytokine deprivation or high-
affinity ligation of antigen receptors as well as calcium-flux or
ER-stress while Puma is most frequently required for cell death in-
duced by DNA-damage, but also acts in concert with Bim upon
growth factor deprivation [17]. Of note, both Bim and Puma effec-
tively limit survival upon aberrant oncogene activation [18,19].
The role of other BH3-only proteins appears more redundant
with or auxiliary to that of Bim or Puma with possible additional
roles in non-apoptotic cell death modalities [20,21].Anti-apoptotic Bcl-2 family members
Bcl-2 was the first described member of the family as being over-
expressed in B cell lymphoma and acting as an oncogene by inhi-
biting apoptosis [22,23]. The other anti-apoptotic Bcl-2 family
members, Bcl-xL, Bcl-w, Mcl-1 and A1/Bfl-1 share up to four Bcl-
2 homology (BH) domains (Fig. 2) and secondary and tertiary
structures [2]. These proteins can bind to Bax/Bak-like proteins al-
though certain preferences exist. As pointed out above, most BH3-Fig. 1 – PhyloTree: unrooted phylogenetic tree http://www.cbrg.
ethz.ch/services/AllAll Mouse proteins: A1-a NP_033872, A1-b
NP_031560, A1-d NP_031562, Bcl-2 AAH95964, Bcl-xL AAA51039,
Bcl-w NP_031563, Mcl1 NP_032588.1 and Boo/Diva AAH52690.only proteins interact only with a subset of Bcl-2 pro-survival ho-
mologues, but the overexpression of any one of these proteins can
protect cells from apoptosis induced by a broad range of stimuli.
This probably reflects their functional overlap, in particular
when highly abundant in cells (reviewed in [2]). The phylogenetic
analysis of these proteins, however, enlightens two distinct sub-
groups of pro-survival homologues: Bcl-2, Bcl-xL and Bcl-w on
one side and Mcl-1, A1/Bfl-1 on the other. Interestingly, Bcl-B/
BOO/DIVA, a more distantly related Bcl-2 family member initially
assigned with pro-apoptotic properties, clusters with Mcl-1 and
A1/Bfl-1 [24] (Fig. 1) suggesting that these genes may have devel-
oped form a common ancestor.
A further distinction within the pro-survival group is their
preferred sub-cellular localization. Bcl-2 is a membrane bound
protein that localizes to the ER, but prefers the mitochondrial
outer membrane, albeit association with nuclear membranes has
also been reported [25]. In contrast, its homologues Bcl-xL and
Bcl-w as well as Mcl-1 are partially cytosolic and often need to
translocate to organelle membranes after cells were exposed to
cytotoxic stimuli [26–28]. While Bcl-xL appears to prefer the ER-
membrane, Bcl-w seems only loosely attached to the outer mito-
chondrial membrane and needs to insert its carboxy-terminus
into it, in response to cell stress [26]. Little however is known
about A1/Bfl-1 in that regard but species specific differences
seem to apply as mouse A1 is preferentially localized in the cyto-
sol, while human A1/Bfl-1 can be found at the mitochondria.
Hence the pro-survival function of A1 seems to be independent
of its localization when overexpressed at high levels [29]. None-
theless, deletion or mutation of the C-term end of either mouse
or human A1 negatively interferes with its anti-apoptotic poten-
tial [30,31]. This indicates that in mice A1's site of anti-apoptotic
action may be imposed by its interaction partners, i.e., the BH3-
only proteins that again can locate to mitochondria [15,32]. In
contrast, human A1 preferentially targets that organelle directly
[30,31].
Also the regulation of gene expression differs significantly
among these anti-apoptotic proteins. Bcl-2 expression appears to
be quite robust in most cell types but in lymphocytes it frequently
changes between different maturation stages. For example, Bcl-2
is high in mature lymphocytes, but low in immature subsets that
undergo active selection processes, such as CD4+8+ thymocytes
or T1 transitional B cells, where Bcl-xL and Mcl-1 seem to be the
preferred pro-survival proteins [33,34] (pers. observations).
Accordingly, different post-transcriptional modes of regulating
Bcl-2 protein abundance and function, including IRES-mediated
translation [35] as well as inactivating phosphorylation events by
“pro-death kinases” such as ASK1 or JNK have been reported [36].
Bcl-xL can be transcriptionally induced by cytokines [37] and growth
factors activating the JAK-STAT pathway [38] ormembers of the TNF
family such as BAFF, e.g. in B cells [39], to name just a few examples.
Mcl-1 expression is transcriptionally regulated by cytokines such as
Il-7 or G-CSF in leukocytes, by IGF-1 signaling in neurons [40] or by
EGF-receptor family members ErbB1 and ErbB2 in 3T3 cells [41].
Beyond rapid transcriptional activation it becomes also rapidly
degraded via the proteasome pathway in response to several apo-
ptotic stimuli, including UV-radiation or cytokine deprivation
[27,42]. Prolonged M-phase arrest in response to microtubule poi-
soning leads to the activation of the spindle check-point and the
gradual decline of Mcl-1 seems to act as an apoptotic timer in the
absence of gene-transcription in mitosis [43].
Fig. 2 – ClustalW2 alignment of mouse Bcl-2 prosurvival homologues http://www.ebi.ac.uk Mouse proteins: A1-a NP_033872, A1-b
NP_031560, A1-d NP_031562, Bcl-2 AAH95964, Bcl-xL AAA51039, Bcl-w NP_031563, Mcl1 NP_032588.1 and Boo/Diva AAH52690.
Highlighted in bold the glutamate 78 of A1 and the corresponding residue of the other anti-apoptotic proteins.
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gene-targeting studies of individual Bcl-2 pro-survival genes dem-
onstrated independent roles and functions in tissue homeostasis
and development. Loss of Bcl-2 causes abnormal death of renal ep-
ithelial cells and melanocyte progenitors as well as mature B and T
lymphocytes [44,45]. Bcl-xL is critical for the survival of erythroid
progenitors as well as neuronal cells during embryogenesis and its
absence causes embryonic death around E14 [46]. Bcl-w is essen-
tial for spermatogenesis [47] and Mcl-1 is already required for im-
plantation of the early embryo [48]. Conditional deletion of Mcl-1
revealed key roles for the survival of hematopoietic stem cells,
immature and mature lymphocytes [49,50], mast cells [51] as
well as neurons [52] or hepatocytes [53].A1/Bﬂ-1 discovery
Murine A1 was originally identified in 1991 as a granulocyte and
macrophage colony stimulating factor (GM-CSF) early response
gene. In a screening approach stimulating bone marrow derived
macrophages with GM-CSF, Orlofsky et al. identified A1 among
six other novel genes showing early transcriptional induction in
response to this cytokine [54]. In 1993 Lin et al. documented A1
expression in thymus, spleen, bone marrow, myeloid and T-
lymphoid cell lines, but not in non-hematopoietic lineages, and
confirmed the induction of A1 in GM-CSF and LPS-stimulated pri-
mary macrophages [55]. Hatakeyama and colleagues mapped
multiple A1 genes on murine chromosome 9 (A1-a, A1-b and
A1-d) and identified also an A1 pseudogene (A1-c) [56]. Of note,
rats and humans express A1 only from one gene locus. All mouse
A1 genes consist of two exons. Exon 1 contains the 82% of the
total open reading frame and exon 2 encodes for the remaining
18% resulting in a 172 amino acid protein. Among the three mu-
rine A1 genes, the exon sequences display 96% of sequence identi-
ty at the nucleotide level and 97% of identity at the protein level,
and also the intronic region (4.7 kb for A1-a; 7.8 kb for A1-b and
A1-d) is very well conserved with 96% sequence identity [56].
A1-c is a pseudogene containing a frame-shift mutation caused
by a single nucleotide insertion resulting in a truncated version
of A1 protein that would only encode for the BH1-domain. Inter-
estingly, the different isoforms of A1 present a different pattern of
expression in the hematopoietic compartment. For example, in
DN4 pre-T cells, A1-d is the major isoform detected [57]. However,
another study reports that A1-b is the predominant form in total
thymocytes, as in resting T and B cells. A1-a seems least abundant
and one study reports its induction in TCR-activated CD8+ T cells,
together with A1-d [37]. In peritoneal macrophages an expression
pattern similar to that noted in T cells was reported, while in neutro-
phils, all A1 isoforms appear expressed at comparable levels [56].
These cell type specific differences may indicate delicate regulation
and different functions of the individual mouse A1 isoforms or,
maybe more likely, different accessibility of the individual A1 pro-
moter regions in multiple cell types conferred by their different epi-
genetic states. However, genetic background differences in the
different mouse strains used for analysis may also contribute and a
direct comparison of the efficacies of these isoforms in cell death
inhibition is actually lacking,
The human A1 gene shares about 72% of sequence identity at the
protein level with mouse A1-a discovered in the early 90s by three
groups. First, it was identified in fetal livers at week 22 of gestationand thus called Bcl-2 related gene in fetal liver (Bfl-1), and discussed
to be involved in stomach cancer development and progression [58].
In a second report, Karsan et al. demonstrated that the expression of
human A1 is not only restricted to the hematopoietic compartment,
as reported before for its murine homologue, but can be detected in
vascular epithelial cells where it is induced in response to TNF-α and
IL-1β, suggesting a role for A1 in protecting endothelial cells during
inflammation [59]. In the third independent study A1 was discov-
ered as a gene involved in a genomic translocation in patients with
CML leukemia. In one patient, the fibroblast growth factor 4 (FGF-
4) gene was truncated and rearranged with the A1 gene, called in
this study Glasgow rearranged sequence (GRS). GRS and A1 se-
quences differ only at two positions (N72T and Q107H). High ex-
pression levels of GRS were also observed in hematopoietic
malignancies, such as chronic myeloid leukemia and the Burkitt
lymphoma cell line Raji [60]. The human A1 gene is located on chro-
mosome 15q24 and consists of three exons giving rise to two differ-
ent splice variants [61,62]. The most abundant mRNA is generated
from exon 1 and exon 2 and is translated into a 175 amino acid
long protein that shares 73% of sequence identity with murine A1-
a. The second transcript variant contains all three exons. This splic-
ing combination causes a shift in the open reading frame, which
leads to premature translational termination after 163 amino acids.
The polypeptide encoded is referred to as Bfl-1_short (s). Bfl-1s con-
tains a hydrophilic C-terminus,which consists of 23 amino acids and
includes four consecutive positively charged amino acids (KKRK),
which are recognized as nuclear localization sequence. However,
the nuclear function of Bfl-1s is still poorly understood. Its mRNA
was found in high levels in lymph nodes, B leukemia cell lines, my-
eloid cell lines and at lower levels in the spleen, but it is lacking in
primary T cells and cell lines. Additionally, overexpression of Bfl-1s
in an acute lymphoblastic leukemia cell line protected against treat-
ment with chemotherapeutic agents [63]. However, its relative
abundance at the protein level is unexplored, as no discriminating
antibodies are available at present.A1/Bﬂ-1 mode of action
A1 shares all four BH-domains with Bcl-2. Of these, the BH1 and
BH2 domains are highly conserved while the BH3 and in particular
the BH4-domain have little homology with those of the cognate
anti-apoptotic proteins. Similar to the other anti-apoptotic Bcl-2
proteins, A1 consists of 8 α-helixes. In particular, the helixes α4,
α5 and α6, corresponding to the BH3, BH1 and BH2 domains re-
spectively, form a groove on the protein surface that is able to in-
teract with the BH3 domain of the pro-apoptotic Bcl-2 family
proteins [64]. Despite the overall structural homology, A1 differs
from all the other anti-apoptotic Bcl-2 family members in its C-
terminal end [65]. While Bcl-2, Bcl-xL, Bcl-w and Mcl-1 localize
predominantly to inner cellular membranes via their hydrophobic
region at the C-terminal end, the C-terminal portion of A1 con-
tains a hydrophilic stretch responsible for ubiquitination and deg-
radation via the proteosome pathway. Interestingly among all the
pro-survival family members only A1 and Mcl-1 show such a
rapid turnover rate. The half-life of A1 and Mcl-1 is estimated to
be as short as 30 min while the half-life of Bcl-2 is estimated to
be around 24 h [29]. Due to the hydrophilic C-terminal portion
of the protein, mouse A1 cannot be anchored at the mitochondrial
outer membrane but can be found associated with membranes, as
Fig. 3 – Ribbon structure of (A) Bfl-1 structure pdb file 2vm6
[65] using Swiss-PdbViewer 4.0.4 act on ribbon showing the
secondary structure. BH1 domain in green, BH2 in blue, BH3 in
yellow BH4 in purple and highlighted the glutamate 78 in the
binding groove in gray. (B) Bcl-2 structure pdb file 2xa0 [72]
using Swiss-PdbViewer 4.0.4 act on ribbon showing the
secondary structure. BH1-domain in green, BH2-domain in
blue, BH3-domain in yellow and BH4-domain in purple.
(C) Alignments using magic fit in Swiss-PdbViewer 4.0.4 on
backbone atoms only. Bfl-1 pdb file 2vm6 [65] red Bcl-2 pdb file
2xa0 [72] blue BH3 only peptide Bim in yellow pdb file 2vm6
[65].
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can be equated with insertion, as reported for Bcl-w, remains to be
investigated. Of note, A1 may interact with all BH-123 proteins, in-
cluding Bok, as well as several BH3-only proteins. Yet, there are con-
flicting reports describing the interaction between A1 with these
proteins. An initial yeast two-hybrid screen identified A1 as a bind-
ing partner of both, Bax and Bak [67]. In a second study using in
vitro translated protein, human A1/Bfl-1 was found to co-
immunoprecipitate only with Bax when its transmembrane domain
was deleted [68]. Other studies performed in a more physiological
context, reported a strong association between both human and
murine A1 and endogenous Bak but not with Bax [69,70]. The inter-
action of A1 with Bax or Bak reflects a preferential binding affinity
that can be found also in the other pro-survivalmembers of the fam-
ily. In general the anti-apoptotic proteins can be subdivided depend-
ing on their ability to interact strongly with either Bax or Bak. The
BH3-only peptide of Bax is able to interact with high affinity with
Bcl-2 and Bcl-w, while Bak peptide binds potently Bcl-xL, Mcl-1
and A1 [71,72]. A1 interacts with different affinity also to the BH3-
only proteins. Competitive binding assays using BH3-peptides
show that A1, similarly to Mcl-1, has no affinity for Bad whereas it
binds very tightly to Bim, Bid and Puma; while Bcl-2, Bcl-xL and
Bcl-w interact potentlywith Bad, Bmf, Bim and Puma [73]. The inter-
action between A1 and Bid or Bim has been confirmed also indepen-
dently in immunoprecipitation assays [29,66,69]. The specific
interaction pattern of A1 is probably due to the presence of an acidic
residue, glutamate 78, within the binding groove that serves as an
interaction surface for the BH3-domains of the pro-apoptotic Bcl-2
family members (Fig. 3). In contrast, all other anti-apoptotic pro-
teins have a hydrophobic or slightly positively charged binding
groove [64]. Moreover, A1 can be stabilized by the interaction with
Bim [29]. The ability to be stabilized by BH3-only proteins and its cy-
tosolic localization suggest that mouse A1might act as a first barrier
against premature or faulty activation of the apoptotic machinery.
However, this feature does not seem to be conserved, as human A1
can target mitochondria, although it is unclear if it could also do so
in the absence of pro-apoptotic Bcl-2 family proteins.
A lot of speculation relates to a putative interaction of A1 with
Noxa that binds preferentially toMcl-1, and, with lower but still sig-
nificant affinity, to A1 [73]. As commercially available antibodies for
both, Noxa and A1, are of limited quality, interaction at the endoge-
nous levels has never been successfully demonstrated. However, a
significant body of circumstantial evidence suggests that interaction
of A1with Noxa can contribute to cell death decisions, as continuous
activation of cell death signals engaging Bcl-2, such as the BH3-
mimetic ABT-737, leads to compensatory upregulation of A1, pro-
moting tumor cell survival and drug resistance [74,75].
Surprisingly, human A1/Bfl-1 can apparently be converted into
a pro-apoptotic factor by a proteolytic cleavage by μ-calpain or a
similar protease activity in response to TNF in the presence of cy-
cloheximide in FL5.12 pro-B cells [30]. Although controversial, A1
is not the only anti-apoptotic protein of the Bcl-2 family reported
to be able to trigger apoptosis. Processing of Bcl-2 [76] or Bcl-x
[77] has been reported to give rise to a pro-apoptotic polypeptide
and a truncated version of Bcl-x, generated by alternative splicing,
Bcl-xS, has also been reported to exert apoptosis enhancing prop-
erties [78]. However, in many of these cases physiological settings
leading to the generation of these fragments have not been de-
fined and data available from the different mouse mutants lacking
these proteins and the associated phenotypes do not reallysupport a pro-apoptotic function of any of these genes. Accordingly,
the physiological relevance of the cleaved A1 polypeptide is not
understood at present and has not been investigated further.
Beside the role in apoptosis, A1, like Bcl-2, Mcl-1 or Bcl-xL can
interact with Beclin1, thereby inhibiting induction of autophagy,
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terestingly, the interaction between Bcl-2 and Beclin1 is mediated
by the BH1 and BH2 domains, which are highly conserved be-
tween A1 and Bcl-2 [64]. Some evidence supports the interaction
between A1 andBeclin1, as A1 knockdown seems to enhance phago-
some–lysosome fusion, thereby limiting growth of Mycobacertium
tuberculosis infected macrophages [80]. However, interaction of
endogenous A1 with Beclin1 remains to be formerly demonstrated.A1/Bﬂ-1 in cancer
A1 transgenic mice fail to develop lymphoma [81], suggesting that,
unlike Bcl-2 [82], A1 is not an oncogene. However, ubiquitination re-
sistant A1 mutants predispose mice to lymphomagenesis when co-
expressed with a dominant-negative mutant of p53 and A1 overex-
pression acceleratedMyc-induced lymphomagenesis inmice [83,84].
A number of hematopoietic malignancies, including B chronic
lymphocytic leukemia (B CLL) [85,86] and acute myeloid leukemia
(AML), are characterized by elevated levels of A1/Bfl-1 and its ex-
pression strongly correlates with chemoresistance and poor prog-
nosis. Interestingly, AML patients with high levels of Wilms Tumor
protein (WT1) show increased A1 expression and show the worst
prognosis and resistance to chemotherapeutic agents [87]. Differ-
entiation of AML cells and acute promyelocytic leukemia (APL)
cells by all-trans retinoic acid (ATRA) is also accompanied by A1
induction via the activation of the transcription and myeloid line-
age commitment factor PU.1 [88]. Also the human promyelocytic
leukemia HL-60 cell line differentiates in neutrophils when trea-
ted with ATRA and thereby rapidly induces A1 and Mcl-1, while
the expression of Bcl-2 and Bcl-xL is downregulated [89]. Hence
it will be interesting to see if ablation of A1 expression or function
can increase the efficacy of these treatments. Of note, aberrant A1 ex-
pression has beendocumented also in a number of non-hematological
malignancies, including breast and stomach cancers and reportedly
associates with metastasizing disease in HCC and melanoma.
Most importantly for current drug-development efforts, A1 seems
to be a primary resistance factor for hematological malignancies trea-
ted with new-generation compounds mimicking the action of BH3-
only proteins, i.e. BH3-mimetics like ABT-737 and its follow up com-
pound, ABT-263. Continuous exposure to ABT-737 induced compen-
satory upregulation of A1 and Mcl-1 in DLBCL lymphoma lines [75]
while in primary B CLL cells derived from lymph nodes upregulation
of Bcl-xL and A1 rapidly induced about 1000-fold resistance to ABT-
737 treatment [74]. Hence, understanding themolecular mechanisms
involved in A1 transcription and post-translational regulation is criti-
cal to improve the efficacy of these compounds. For a more detailed
overview on the role of A1 in cancer and drug resistance we want to
refer to an excellent recent review by Meike Vogler [90].A1/Bﬂ-1 in lymphocyte development and function
MurineA1 is expressed inmultiple organs in the embryo including the
developing nervous system, liver, heart and cartilaginous primordial
skeleton from embryonic day 15.5. However, in adult mice A1 expres-
sion seems to be restricted to the hematopoietic compartment (Fig. 4).
In the T cell lineage A1 can be first detected in double negative thymo-
cytes, where its expression is induced via the PLCγ/PKC/NF-kB path-
way upon pre-TCR signaling [91]. More precisely, A1 is expressedduring the transition from the DN3 (CD44−CD25+CD4−CD8−) to
the DN4 (CD44−CD25−CD4−CD8−) stage of thymocyte development
where “beta-selection” occurs. The functional importance of A1 at this
stage was demonstrated by two findings: (i) A1 overexpression pro-
motes survival of Rag-1−/− pre-TCR thymocytes [57] and (ii) reduc-
tion of A1 expression in A1-knockdown mice leads to a significantly
reduced percentage of DN4 and DP cells with a relative increase in
DN2 and DN3 thymocytes. In this animal model, we have expressed
an shRNA targeting all A1 isoforms, embedded in the microRNA-30
(miR30) backbone, under control of the hematopoiesis-specific
Vav-gene promoter. In a second model, we have tested an alterna-
tive shRNA sequence targeting all mouse A1 isoforms under control
of the tetracycline responsive TRE-CMVmin promoter and expressed it
conditionally using a Tet-transactivator (tTA), driven by theVav-gene
promoter, yielding similar results (Ottina et al., in revision). This
strongly indicates that A1 is necessary and sufficient for further
differentiation of DN3 thymocytes. While IL-7-mediated Mcl-1 ex-
pression is necessary at the DN2 stage of thymocyte development
[50] and Bcl-2 overexpression can restore thymocyte development
in Il7R−/− mice [92], A1 seems to play a unique role in promoting
survival of thymocytes receiving signals via their pre-TCR.
Once cells become CD4+8+ double positive (DP) thymocytes,
A1 is down regulated and then re-induced in single positive (SP)
thymocytes in particular in CD4+ cells where A1 expression is
up to 30 fold higher compared to the DP subgroup [37]. In line
with this observation A1 knockdownmice have a reduced propor-
tion of CD4+ and increasing amounts of CD8+ thymocytes (Ottina
et al. in revision), functionally showing that the high A1 expres-
sion in this thymic subset is indeed required for their survival.
Enforced expression of A1 driven from a CD2-minigene in F5-TCR
transgenic Rag−/− mice induces accumulation of DP thymocytes,
but does not seem to affect negative selection by exogenous ad-
ministration of the NP68 peptide of influenza [93]. A1 seems to
be also involved in the survival of Th1/Th2 T lymphocytes. Reti-
noid X receptor (RXR) agonist treated CD4+ thymocytes induced
A1-d and A1-b expression specifically during Th2 differentiation
that depends on IL-4, IL-12 and IFN-γ stimulation [94]. In lymph
node derived T cells A1 expression is not detectable under steady
state conditions, but it is strongly upregulated in response to TCR
engagement, similar to Noxa, which may need to be antagonized
early in the immune response allowing survival of high-affinity
TCR-bearing antigen-specific T cell clones [95]. TCR stimulation
alone induces NF-kB and MEK/ERK signaling which can trigger
A1 expression, along with PI3K-dependent Bcl-xL induction, and
proliferation of lymphocytes [37,96]. In agreement with these
findings, A1 is also induced within 6 h by ConA activation in sple-
nocytes and then rapidly decreases to basal levels by day 3, while
Bcl-2 mRNA levels were induced only after 24 h post activation
and remained high till day 4 post activation. Interestingly, A1 ex-
pression in CD8+ activated T cells is not dependent on cytokines
such as IL-2, IL-4, IL-7 and IL-15, which in turn are required to in-
crease Bcl-2 expression [37]. In contrast to Bcl-2, A1 overexpres-
sion in lck-A1-a transgenic mice protects splenic T cells from
apoptosis without inhibiting their proliferation [97], but cannot
prevent activated T cells from cell death induced by re-
stimulation of the TCR that is actually CD95-dependent [1].
Together, these findings show that A1 is an early regulator of
TCR-mediated survival of T lymphocytes and, since its expression
does not inhibit cell proliferation, allows an efficient accumulation
of T cells upon antigen stimulation.
Fig. 4 – A1 in leukocyte development. Schematic overview of hematopoiesis with key-check points indicated in which developing
leukocytes rely on A1 expression for progression and/or survival. Abbreviations used: hematopoietic stem cell (HSC), common
myeloid progenitor (CMP), common lymphoid progenitor (CLP), B cell (B), germinal center (GC), double negative thymocyte (DN),
double positive (DP), single positive (SP), T cell (T).
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at very low levels, but apparently might have a role in the survival
of early B cells as transgenic mice expressing A1-a under the con-
trol of the IgH gene enhancer in the B cell lineage (Eμ-A1-a) show
an accumulation of pro-B cells and proportional decrease of class-
switched mature B cells in the periphery. However, A1 overex-
pression in SCID mice did neither promote V(D)J rearrangement
nor rescue pre-B cells, as seen in Eμ-Bcl-2 transgenic SCID mice
[81]. Similar to Bcl-2, A1 is up-regulated in peripheral B cells
[98,99], which is in contrast to Mcl-1 and Bcl-xL that are already
found expressed in pro/pre-B cells, but at lower levels in mature
B cells [100–102]. In particular, A1 is upregulated during differen-
tiation from transitional (T) B cells (IgMhigh, CD24+, CD21−) to
follicular (FO) B cells (IgMlow, IgD+, CD24+, CD21+) in the spleen.
At this stage, FO B cells become also dependent on the TNF family
cytokine BAFF for survival, but results related to BAFF-dependent
induction of A1 are contradictory [99,103]. Nevertheless, induc-
tion of A1 is dependent on the PLC-γ2 pathway and consequent
activation of Nf-κB via the BCR [104], considered to be essential
for B cells to fully mature. Consistently, A1 overexpression is suffi-
cient to rescue survival of mature FO B cells in the absence of PLC-
γ2 [105]. Since A1 expression is strongly induced upon BCR signals
on FO B cells, but not on transitional type 1 (T1) B cells, the latter
can still undergo clonal deletion in response to autoreactive BCRsignals while follicular B cells become less susceptible to this trig-
ger [105]. Accordingly, the immature WEHI231 mouse B cell lym-
phoma line undergoes apoptosis in response to BCR stimulation,
which can be prevented by co-stimulatory CD40 signals known
to strongly upregulate A1 [106]. Consistent with these findings, B
cells from SLE patients show increased levels of A1/Bfl-1 [107].
These results indicate the essential role of A1 upon antigen stimu-
lation of mature B cells, but the role of A1 on B cell effector func-
tion is still unclear. Our own results using B cells derived from
A1 knockdown mice support a role for A1 as a key survival factor
for mature FO B cells as their percentage is decreased in these an-
imals. This finding correlated with increased sensitivity of transition-
al type 2 (T2) and FO B cells to BCR ligation-mediated killing ex vivo
and impaired proliferation of splenic B cells upon mitogenic stimula-
tion (Ottina et al., in revision).A1/Bﬂ-1 in the development and function of myeloid
cells
A1 was originally identified in bone marrow derived macrophages
treated with GM-CSF [55]. Since then its role in the myeloid com-
partment has been widely studied. Under steady state conditions
neutrophils are short-lived. However, upon infection and in response
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allowing the effective clearance of bacteria. A1 is expressed in both
murine and human neutrophils and is induced via NF-kB signals in
response to bacterial endotoxins like LPS or pro-inflammatory cyto-
kines, such as G-CSF, GM-CSF, TNFα, IFN-γ or IL-8, all extending cell
survival [55,89]. Neutrophils derived from mice lacking one of the
three functional A1 isoforms, A1-a, have a higher spontaneous apo-
ptosis rate or when exposed to LPS ex vivo do no longer respond
with increased survival, indicating that A1 is the main inhibitor of
neutrophil apoptosis [108]. However, A1-a−/− mice have normal
granulocyte numbers under (i) steady state as well as (ii) inflamma-
tory conditions induced by i.p. injection of peptone. This indicates
that bone marrow resident progenitors do still have sufficient clono-
genic capacity to produce sufficient neutrophils A1-a knockout mice
[108].
Our own results using in vivo RNAi to knockdown all A1 iso-
forms in transgenic mice show that dependent on the rate of
knockdown achieved, granulocytes fail to accumulate in these an-
imals or die most rapidly ex vivo. We also noted that the clono-
genic potential of bone marrow derived myeloid progenitors
from these mice show reduced capacity to form granulocytic colo-
nies, particularly under conditions of delayed cytokine addition
(Ottina et al., in revision). This indicates that A1 may not only be
critical for mature granulocyte survival but possibly also for the
survival and/or differentiation of their progenitors.
As mentioned above, A1 is constitutively expressed in neutro-
phils while it is induced by inflammatory cytokines such as INF-
γ in macrophages. In particular A1-a is the isoform with maximal
fold-induction in inflammatory macrophages [109]. Treatment
with LPS or Mycobacterium bovis derived Bacillus Calmette-
Guerin (BCG), or Toxoplasma gondii elicts the expression of A1 in
the first 8–16 h post infection via the NF-kB signaling pathway,
which then decreases by 24 h [109–111]. The expression of A1
correlated with increased macrophage survival upon infection
with BCG and nitric oxide resistance, while macrophages derived
from A1-a−/− mice fail to be protected [109]. On the one hand
A1 seems to be essential for macrophage survival upon infection
but on the other hand A1 is possibly a negative regulator of the
autophagosome maturation in virulent mycobacteria infected
macrophages. In particular, inMycobacterium tubercolosis infected
macrophages, A1 overexpression inhibits the maturation and
acidification of mycobacterial phagosomes by the inhibition of
the autophagy pathway [111]. Since A1 inhibits the apoptosis of
the infected macrophages [80] but also the killing of intracellular
mycobacteria in autophagosome maturation, the virulent
M. tubercolosis strain is able to survive within the host.
Together with Mcl-1 [51], A1 seems to play a key role in the
mediation of mast cell survival and subsequent severity of allergic
reactions. Mast cells are long-lived myeloid cells that reside in the
tissue and skin where they participate in inflammatory responses
to infection and parasites, but they can also cause allergic reac-
tions. These cells are characterized by the presence of granules
rich in histamine, heparin, leukotriens, prostaglandin and other in-
flammatorymediators that can be released via the activation of their
IgE receptor, FcεR1, which also promotes their cell survival. De-
granulated mast cells are therefore able to re-granulate and be acti-
vated repeatedly leading to the perpetuation of the allergic re-
sponse. Both murine and human A1 are induced in mast cells
already 2 h post IgE receptor activation [112] by a mechanism
which is dependent on NF-AT activation and calcium release, butNF-kB independent [113,114]. Interestingly, inflammatory stimuli
such as GM-CSF, SCF, IL-4 or TNF-α fail to induce A1 in mast cells,
contrary to what has been observed in granulocytes and macro-
phages. Crosslinking of the FcεR1 induces A1 to promote survival,
which is diminished in mast cells derived from A1-a−/− mice chal-
lenged ex vivo [112].Non-hematopoietic functions of A1/Bﬂ-1
Outside the hematopoietic system, A1 expression was observed in
vascular endothelial (VEC) and smooth muscle cells (SMC) after
stimulation with pro-inflammatory cytokines (IL-1β, TNF-α) or
PMA [59]. In endothelial cells, A1 can confer protection to TNF-α
and ceramide-induced apoptosis [115]. In addition, high levels of
human A1 were detected in the lung, moderate levels in the intes-
tine and testis and lower extent in the heart, placenta, skeletal
muscle, pancreas, colon and prostate [59]. However, this wide-
spread expression pattern might actually result from contaminating
hematopoietic cells, VEC or SMC.
Atherosclerosis is characterized by increased VSMC prolifera-
tion and is accelerated in diabetic patients. Increased A1 expres-
sion in VSMC might contribute to the development of vascular
disease as it was shown that high glucose levels augment A1 and
Bcl-xL expression and cell death protection in coronary artery
smooth muscle cells [116].
A protective role for A1 in hyperoxic acute lung injury (HALI),
induced by high O2 concentrations after treatment of patients suf-
fering from pulmonary or cardiac diseases was also reported. Ad-
ditionally, IL-11 and VEGF can mediate protective functions in
HALI by inducing A1, which was abolished in A1-a knockout
mice [117].
A1 might also be cytoprotective in Alzheimer disease. The n-3
fatty acid, docosahexaenoic acid and its derivative, neuroprotectin
D1 (NPD1) that is reduced in the hippocampal cornu ammonis region
1 in Alzheimer patients, induces expression of pro-survival Bcl-2,
Bcl-xL and A1 [118].
Finally, conflicting results have been reported on A1 expression
in the mammary gland. Augmented A1 levels were observed in
mammary tissue upon forced weaning of pregnant mice that
might contribute to the delayed involution observed in such animals
[119]. However, other reports showed A1 downregulation during
involution depending on the genetic background of the mouse
strains used [120]. A more detailed analysis of these phenomena is
required given a possible role of A1 in breast cancer [90].Concluding remarks
20 years after its initial description, we have gathered some evi-
dence of A1 function in leukocyte development and hematological
disorders. However, we know very little about A1 function outside
the hematopoietic system or the E3-ligases involved in its rapid
turnover. Generation of reliable antibodies, recognizing endoge-
nous A1, the detailed analysis of recently generated in vivo knock-
down mouse models (Ottina et al., in revision) and sophisticated
future gene-targeting will help to better define A1 function in nor-
mal physiology and disease. Given its proposed role in drug-
resistance, tumor progression and metastasis as well as its associ-
ation with autoimmunity in humans, selective inactivation of its
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optimized versions of peptide aptamers [121] should help to
improve treatment strategies for multiple human pathologies.Acknowledgments
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